Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2020-10-20 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
第四届监事会第十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 10th meeting of the 4th Supervisory Board of Yunnan Watson Biotechnology Co., Ltd. It includes approvals of the company's 2020 Q3 report, asset impairment provisions, stock option plan adjustments, and a proposal for issuing H shares and listing on the Hong Kong Stock Exchange. The document is a meeting resolution announcement by the supervisory board, not the actual quarterly report or financial statements. It also references that the full 2020 Q3 report is available on the designated disclosure website, indicating this document is not the report itself but an announcement of supervisory board decisions and approvals. The document length is 4060 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the best fitting category is Regulatory Filings (RNS), as it is a regulatory announcement of supervisory board meeting resolutions and approvals related to financial reports and capital issuance plans, but does not contain the full financial report or detailed financial data itself.
2020-10-20 Chinese
北京国枫律师事务所关于公司调整2018年股票期权激励计划股票期权行权价格的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the adjustment of the exercise price of stock options under the company's 2018 stock option incentive plan. It references relevant laws and regulations, details the approval procedures by the board and shareholders, and confirms the legality and compliance of the adjustment. The document is a standalone legal opinion related to stock option adjustments, not a financial report, earnings release, or management discussion. It does not contain financial statements or earnings data. It is not an announcement of a report but a legal opinion letter. This type of document fits best under Regulatory Filings (RNS) as it is a compliance/legal document related to corporate governance and securities law, but does not fit other more specific categories like MANG or CAP.
2020-10-20 Chinese
关于公司参与投资设立产业基金并签署合伙协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a listed company (Yunnan Watson Biotechnology Co., Ltd.) regarding its participation in establishing an industrial fund and signing a partnership agreement. It details the investment overview, parties involved, fund structure, investment terms, and potential risks. The document is a formal disclosure of a financing/investment activity by the company, including capital contribution and fund management details. It does not contain financial statements, earnings data, or management discussion of financial results. It is not a report like an annual or interim report, nor is it a call transcript or governance document. The content fits best under Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes through investment in a fund.
2020-10-20 Chinese
关于2020年第三季度计提资产减值准备及核销资产的公告
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from a company about its asset impairment provisions and asset write-offs for the third quarter of 2020. It includes specific financial figures related to impairment of receivables, inventory, and fixed assets, as well as the impact on net profit. The document references accounting standards and regulatory guidelines, and includes opinions from the audit committee, independent directors, and supervisory board. The content is focused on a specific quarterly period and contains substantive financial data and analysis related to asset impairment. This fits the definition of an Interim / Quarterly Report (IR), as it is a comprehensive financial report for a period shorter than a full fiscal year and contains actual financial statements and detailed financial analysis, not merely an announcement or certification. Therefore, the appropriate classification is IR with high confidence. Q3 2020
2020-10-20 Chinese
独立董事关于第四届董事会第十三次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on several company matters including asset impairment provisions for Q3 2020, adjustments to a 2018 stock option plan, and a proposal for issuing H shares and listing on the Hong Kong Stock Exchange. It references regulatory guidelines and company governance procedures. The document is not a full financial report but rather an opinion statement related to board meeting matters and corporate governance decisions. It does not contain comprehensive financial statements or detailed financial analysis. The content aligns with Board/Management Information (MANG) as it discusses board-level decisions and approvals related to company management and governance.
2020-10-20 Chinese
第四届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 13th meeting of the 4th Board of Directors of Yunnan Watson Biotechnology Co., Ltd. It includes multiple board decisions such as approval of the 2020 Q3 report, asset impairment provisions, investment in a fund, stock option plan adjustments, and plans for issuing H shares and listing on the Hong Kong Stock Exchange. The document is a formal board meeting resolution announcement, not the actual financial report or detailed financial statements. It also includes voting results and references to further announcements on the information disclosure website. This fits the category of Board/Management Information (MANG) as it primarily concerns board meeting decisions and management resolutions rather than the full annual or quarterly report or other filings.
2020-10-20 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.